Phospho-RPS6KB1 (Ser411) Antibody

What is RPS6KB1 and why is phosphorylation at Ser411 significant?

RPS6KB1 (also known as p70 S6 kinase, S6K1, p70-S6K, and several other names) is a key regulator of mRNA translation that plays critical roles in cell cycle progression through the G1 phase in proliferating cells and in synaptic plasticity of terminally differentiated neurons. Phosphorylation at Ser411, one of the proline-directed sites in the autoinhibitory domain near the C-terminus, is specifically required for the rapamycin-sensitive phosphorylation of Thr389 and subsequent activation of S6K1 . This hierarchical phosphorylation represents a crucial regulatory mechanism, as mutation of Ser411 to Ala has been shown to abolish insulin-induced Thr389 phosphorylation and S6K1 activation .

What are the common applications for Phospho-RPS6KB1 (Ser411) antibodies?

Phospho-RPS6KB1 (Ser411) antibodies are widely applied in multiple experimental techniques:

• Western Blot (WB): Primary application for detecting phosphorylation status of RPS6KB1 at Ser411 in cell lysates

• Immunohistochemistry (IHC): Used for tissue localization of phosphorylated RPS6KB1

• Immunofluorescence (IF): Applied for cellular localization studies

• Immunoprecipitation: Used to isolate the phosphorylated form of the protein for downstream analyses

These applications enable researchers to track the activation status of S6K1 in various experimental contexts, including agonist stimulation, drug treatments, and genetic manipulations.

What cell types or tissues typically express phosphorylated RPS6KB1 at Ser411?

Phosphorylation of RPS6KB1 at Ser411 has been documented in multiple cell types and tissues:

• Nervous system neurons: Where Cdk5-p35 kinase associates with S6K1 and catalyzes phosphorylation specifically at Ser411

• Monocytes: Demonstrated in IFN-γ-activated human peripheral blood monocytes

• Adipocytes: Observed in insulin-stimulated 3T3-L1 adipocytes

• Hepatocytes: Present in HepG2 cells following mTORC1 agonist treatment

The phosphorylation pattern varies based on cell type and stimulus, making it important to establish appropriate positive controls for your specific experimental system.

What are the optimal protocols for detecting phospho-RPS6KB1 (Ser411) in Western blots?

For optimal Western blot detection of phospho-RPS6KB1 (Ser411):

• Sample preparation:

  • Rapidly lyse cells in buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • Maintain samples at 4°C throughout processing

  • Include protease inhibitors to prevent degradation

• Recommended dilutions:

  • Primary antibody: 1:1000 is typically effective for most commercial Phospho-RPS6KB1 (Ser411) antibodies

  • Secondary antibody: 1:5000-1:10000 HRP-conjugated anti-rabbit IgG (as most Phospho-RPS6KB1 antibodies are rabbit-derived)

• Detection considerations:

  • Expected molecular weight: 70 kDa for p70S6K1; some antibodies may also detect the 85 kDa isoform

  • Signal enhancement systems may be required for low abundance phosphorylation

  • Include positive controls (e.g., insulin-stimulated adipocytes or IFN-γ-stimulated monocytes)

• Specificity validation:

  • Include non-phosphorylated controls (e.g., serum-starved cells)

  • Consider phosphatase treatment of duplicate samples as negative controls

  • For definitive validation, include samples from cells expressing S411A mutant RPS6KB1

How can I validate the specificity of Phospho-RPS6KB1 (Ser411) antibodies?

Validating antibody specificity is crucial for reliable research. For Phospho-RPS6KB1 (Ser411) antibodies:

• Peptide competition assay:

  • Pre-incubate antibody with phosphorylated peptide used as immunogen

  • Compare signal with untreated antibody; specific signal should be diminished or eliminated

• Genetic approaches:

  • Compare signal in wild-type cells versus cells expressing S411A mutant RPS6KB1

  • Use RPS6KB1 knockdown/knockout cells as negative controls

• Phosphatase treatment:

  • Treat duplicate samples with lambda phosphatase before immunoblotting

  • Specific phospho-signals should be eliminated

• Stimulus-dependent phosphorylation:

  • Compare unstimulated versus stimulated conditions (e.g., before/after insulin treatment)

  • Specific phospho-signals should increase after stimulation

• Cdk5 inhibition:

  • Since Cdk5-p35 kinase catalyzes S6K1 phosphorylation at Ser411, inhibition of Cdk5 (e.g., with roscovitine) should decrease the signal

What controls should be included when using Phospho-RPS6KB1 (Ser411) antibodies?

When using Phospho-RPS6KB1 (Ser411) antibodies, include these essential controls:

Including these controls helps ensure experimental rigor and facilitates accurate interpretation of results.

How does Ser411 phosphorylation interact with other phosphorylation sites on RPS6KB1?

RPS6KB1 activation involves a complex, hierarchical phosphorylation cascade with important interdependencies:

• Relationship between Ser411 and Thr389 phosphorylation:

  • Ser411 phosphorylation is required for the rapamycin-sensitive phosphorylation of Thr389

  • Mutation of Ser411 to Ala ablates insulin-induced Thr389 phosphorylation

  • Phosphomimetic mutation of Thr389 overcomes the inhibitory effect of S411A mutation

• Coordinated phosphorylation with other C-terminal sites:

  • S6K1 contains multiple phosphorylation sites in its C-terminal domain, including Ser411, Ser418, Thr421, and Ser424

  • Cdk5-mediated phosphorylation of both Ser424 and Ser429 is required for differential target phosphorylation

  • While Ser411 phosphorylation influences Thr389 phosphorylation, phosphorylation of other canonical S6K1 activation sites (Thr229, Ser371) appears unaffected by Cdk5 inhibition

• Functional consequence of combinatorial phosphorylation:

  • Different patterns of phosphorylation direct S6K1 toward specific substrates

  • S6K1 phosphorylated at Thr389, Ser424, and Ser429 (designated S6K1*) shows altered substrate specificity compared to S6K1 phosphorylated only at Thr389

This complex phosphorylation pattern creates distinct S6K1 proteoforms with potentially different substrate preferences and cellular functions.

What kinases are responsible for phosphorylating RPS6KB1 at Ser411 in different cellular contexts?

The phosphorylation of RPS6KB1 at Ser411 involves different kinases depending on cellular context:

• Neuronal cells:

  • Cdk5-p35 kinase directly phosphorylates S6K1 at Ser411

  • Cdk5 associates with S6K1 via direct interaction between p35 and S6K1

  • Inhibition of Cdk5 activity or suppression of Cdk5 expression blocks S6K1 phosphorylation at Ser411

• Proliferating cells:

  • CDK family members are implicated, as treatment with the CDK inhibitor roscovitine blocks S6K1 phosphorylation at Ser411

  • JNK1 has been shown to phosphorylate S6K at C-terminal S/T-P sites, potentially including Ser411

  • The specific CDK member responsible may vary by cell type

• Stimulus-dependent phosphorylation:

  • In IFN-γ-stimulated monocytes: Cdk5 is essential for Ser411 phosphorylation

  • In insulin-stimulated adipocytes: Similar Cdk5-dependent mechanism

This context-dependent phosphorylation highlights the importance of considering cell type and stimulus when studying S6K1 regulation.

How can Phospho-RPS6KB1 (Ser411) antibodies be used to study differential substrate targeting by S6K1?

Phospho-RPS6KB1 (Ser411) antibodies can be powerful tools for investigating how specific phosphorylation patterns direct S6K1 toward different substrates:

• Comparative substrate phosphorylation analysis:

  • Use Phospho-RPS6KB1 (Ser411) antibodies alongside antibodies to other phosphorylation sites (e.g., Thr389, Ser424, Ser429)

  • Compare phosphorylation patterns with substrate-specific phosphorylation (e.g., RPS6 at Ser235/236 versus EPRS at Ser999)

  • Research indicates that while RPS6 phosphorylation requires only Thr389 phosphorylation, EPRS phosphorylation requires additional Cdk5-dependent phosphorylation at Ser424/Ser429

• Immunoprecipitation-based approaches:

  • Use Phospho-RPS6KB1 (Ser411) antibodies to immunoprecipitate specifically phosphorylated forms

  • Perform in vitro kinase assays with different substrates to assess substrate selectivity

  • Combine with mass spectrometry to identify associated proteins in different phosphorylation states

• Experimental manipulation of phosphorylation:

  • Compare substrate phosphorylation in cells expressing wild-type S6K1 versus phospho-mutants (S411A, S411D)

  • Use Cdk5 inhibitors to block Ser411 phosphorylation and examine effects on different substrates

  • Results suggest Cdk5 inhibition blocks EPRS phosphorylation while leaving RPS6 phosphorylation intact

This approach can reveal how combinatorial phosphorylation creates a "phospho-code" that directs S6K1 activity toward specific substrates.

Why might I detect multiple bands when using Phospho-RPS6KB1 (Ser411) antibodies?

Multiple bands in Western blots using Phospho-RPS6KB1 (Ser411) antibodies can occur for several reasons:

• Isoform detection:

  • The p70 (70 kDa) and p85 (85 kDa) isoforms of S6K1 differ only by an N-terminal nuclear localization sequence in p85

  • Both isoforms contain the Ser411 phosphorylation site (corresponding to Ser434 in p85)

  • Many commercial antibodies detect both isoforms

• Degradation products:

  • Phosphorylated S6K1 may be less stable and subject to proteolytic degradation

  • JNK1-mediated phosphorylation makes S6K protein unstable in the absence of IKK2 activation

  • Include fresh protease inhibitors and maintain cold temperature during sample processing

• Cross-reactivity:

  • Some antibodies may cross-react with related kinases or phosphorylation sites

  • Validate specificity using peptide competition, phosphatase treatment, or genetic approaches

• Post-translational modifications:

  • Additional modifications (ubiquitination, SUMOylation) may alter migration

  • Differential phosphorylation at multiple sites creates distinct mobility populations

If encountering multiple bands, perform careful validation experiments to distinguish specific from non-specific signals.

How should I interpret changes in Ser411 phosphorylation relative to total RPS6KB1?

Interpreting changes in Ser411 phosphorylation requires careful consideration of several factors:

• Normalization approaches:

  • Always normalize phospho-signal to total RPS6KB1 protein levels

  • Use identical samples on parallel blots or strip and reprobe membranes

  • Calculate phospho/total ratio to distinguish phosphorylation changes from expression changes

• Context-dependent interpretation:

  • In normal signaling: Increased Ser411 phosphorylation typically precedes Thr389 phosphorylation and kinase activation

  • Following Cdk5 inhibition: Expect decreased Ser411 phosphorylation without changes in total protein

  • In stress conditions: JNK1-mediated phosphorylation may destabilize S6K1, causing both decreased phosphorylation and total protein

• Relationship to functional outcomes:

  • Correlate Ser411 phosphorylation with downstream substrate phosphorylation (e.g., RPS6, EPRS)

  • Assess functional outcomes (translation rates, cell growth) alongside phosphorylation changes

  • Consider that specific substrate targeting may depend on combinatorial phosphorylation patterns

• Temporal dynamics:

  • Ser411 phosphorylation initiates the activation cascade but may decrease after prolonged stimulation

  • Include appropriate time-course experiments to capture the dynamic nature of the phosphorylation events

A comprehensive interpretation should consider these multiple aspects rather than viewing phosphorylation in isolation.

What experimental artifacts commonly occur with Phospho-RPS6KB1 (Ser411) antibodies and how can they be avoided?

Several experimental artifacts can complicate the interpretation of results when using Phospho-RPS6KB1 (Ser411) antibodies:

• Dephosphorylation during sample preparation:

  • Phosphorylation is rapidly lost if phosphatase inhibitors are inadequate

  • Solution: Include multiple phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) in all buffers and maintain samples at 4°C

• Non-specific bands:

  • Background bands may appear due to cross-reactivity with related phosphoproteins

  • Solution: Optimize antibody dilution, blocking conditions, and washing steps; validate with phospho-peptide competition assays

• Cell density effects:

  • Confluent cells often show altered baseline phosphorylation of S6K1

  • Solution: Standardize cell culture conditions and harvesting at consistent densities

• Rapamycin-insensitive phosphorylation:

  • Some experimental conditions may generate rapamycin-insensitive Ser411 phosphorylation

  • Solution: Include appropriate controls (rapamycin treatment, Cdk5 inhibitors) to confirm pathway specificity

• Antibody lot variability:

  • Different lots may show variable specificity and sensitivity

  • Solution: Validate each new lot against previous lots using defined positive controls

Careful experimental design and thorough controls can minimize these potential artifacts and ensure reliable results.

How is Phospho-RPS6KB1 (Ser411) implicated in disease mechanisms and therapeutic targeting?

The phosphorylation of RPS6KB1 at Ser411 has emerging significance in disease mechanisms:

• Cancer signaling:

  • Hyperactivation of the mTOR-S6K1 pathway occurs in many cancers

  • The hierarchical phosphorylation pattern involving Ser411 represents a potential regulatory node

  • Disrupting specific phosphorylation patterns might enable more selective targeting than complete S6K1 inhibition

• Neurological disorders:

  • Cdk5 hyperactivation occurs in neurodegenerative conditions including Alzheimer's disease

  • Cdk5-mediated phosphorylation of S6K1 at Ser411 may link aberrant Cdk5 activity to translational dysregulation

  • This connection provides potential therapeutic targets at the intersection of Cdk5 and mTOR pathways

• Metabolic diseases:

  • S6K1 is implicated in insulin resistance and type 2 diabetes

  • The regulatory role of Ser411 phosphorylation in insulin signaling suggests it may influence metabolic homeostasis

  • Understanding this specific phosphorylation may reveal new approaches to improve insulin sensitivity

Research in these areas is ongoing, with phosphosite-specific antibodies serving as critical tools for investigating these disease mechanisms.

What are the latest methods for studying dynamic changes in Ser411 phosphorylation in live cells?

Recent methodological advances enable more sophisticated analysis of Ser411 phosphorylation dynamics:

• Phospho-specific biosensors:

  • FRET-based biosensors can detect conformational changes associated with specific phosphorylation events

  • While not yet widely available for Ser411, similar approaches for other S6K1 phosphosites provide templates for development

• Proximity ligation assays (PLA):

  • Combines antibody-based detection with DNA amplification for high sensitivity

  • Can detect endogenous Ser411 phosphorylation in fixed cells with spatial resolution

  • Useful for detecting low-abundance phosphorylation events in specific subcellular compartments

• Mass spectrometry approaches:

  • Parallel Reaction Monitoring (PRM) allows quantitative tracking of specific phosphopeptides

  • SILAC or TMT labeling enables comparative analysis across multiple conditions

  • Phosphoproteomics can reveal how Ser411 phosphorylation correlates with global phosphorylation networks

• Genetic approaches:

  • CRISPR-based knock-in of phospho-mimetic or phospho-deficient mutations

  • Optogenetic control of kinases enables temporal manipulation of phosphorylation events

  • These approaches can complement antibody-based detection methods

These emerging technologies allow researchers to move beyond static snapshots toward understanding the dynamic regulation of S6K1 phosphorylation in living systems.

How do multisite phosphorylation patterns including Ser411 create a "phospho-code" for differential substrate targeting?

Recent research reveals a sophisticated "phospho-code" in which specific patterns of phosphorylation direct S6K1 toward different substrates:

• Combinatorial phosphorylation patterns:

  • While Thr389 phosphorylation is sufficient for phosphorylation of some substrates (e.g., RPS6), others (e.g., EPRS) require additional phosphorylation at sites including Ser424 and Ser429

  • Ser411 phosphorylation appears to be permissive for Thr389 phosphorylation, placing it hierarchically upstream in the activation cascade

  • Different stimuli may induce distinct phosphorylation patterns that direct S6K1 toward specific substrate sets

• Structural mechanisms:

  • Phosphorylation in the C-terminal region (including Ser411) relieves autoinhibition

  • The specific pattern of phosphorylation may induce distinct conformational changes that expose different substrate-binding surfaces

  • These conformational changes potentially alter recognition of substrate consensus sequences

• Experimental evidence for differential targeting:

  • S6K1 isolated from IFN-γ-activated cells phosphorylates both EPRS linker and RPS6

  • S6K1 isolated from Cdk5-inhibited cells phosphorylates RPS6 but not EPRS linker

  • This differential substrate selection depends on phosphorylation at Ser424 and Ser429, potentially in cooperation with Ser411

This phospho-code concept represents a sophisticated regulatory mechanism that allows cells to direct S6K1 activity toward specific targets in response to different stimuli.